# A Study of LY3493269 in Participants With Type 2 Diabetes

> **NCT04515576** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 56 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LY3493269
- **DRUG:** Dulaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04515576
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-25
- **Primary completion:** 2021-03-09
- **Final completion:** 2021-03-09
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04515576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04515576, "A Study of LY3493269 in Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04515576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*